Yvette C. Terrie

DocwireNews

Results from a study published in the <a href="https://www.annalsofoncology.org/article/S0923-7534(25)00134-6/fulltext" target="_blank" rel="noopener">Annals of Oncology</a> revealed that in clinically relevant settings, the use of the cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) palbociclib, ribociclib, and abemaciclib is associated with different outcomes, highlighting the value of patient-centered treatment plans.The cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) palbociclib, ribociclib, and abemaciclib in combination with endocrine therapy (ET) are the standard-of-care, first-line treatment for patients diagnosed with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer&nbsp; (HR+/HER2- aBC).The authors wrote, &ldquo;The three CDK4/6i have different pharmacology and safety, but no large effectiveness comparisons have been conducted so far.&rdquo;The PALMARES-2 study is a multicenter observational study that encompasses both retrospective and prospective data collection to evaluate the effectiveness of the cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), including palbociclib, ribociclib, and abemaciclib for the treatment of HR+/HER2- aBC.The primary study endpoint was real-world progression-free survival (rwPFS), and multivariable Cox regression models were employed to modify the correlation between individual CDK4/6i and rwPFS for clinically relevant variables.The study cohort comprised of 1,982 patients who initiated therapy from January 2016 to September 2023.Results revealed that of 1,982 patients registered in the PALMARES-2 study, 789, 736, and 457 patients received palbociclib, ribociclib, and abemaciclib, respectively.The average rwPFS was reported as 34.1 months.The authors noted, &ldquo;In the whole study cohort, abemaciclib and ribociclib were associated with better rwPFS when compared to palbociclib (adjusted HR [aHR] 0.76, 95% CI 0.63-0.92; P=0.004 and aHR 0.83, 95% CI 0.73-0.95; P=0.007, respectively).&rdquo;The results also revealed that, compared to palbociclib, only using abemaciclib was associated with better rwPFS among patients with endocrine-sensitive disease.On the contrary, among patients who were premenopausal or had endocrine-resistant or luminal B-like disease, the use of abemaciclib and ribociclib was more effective than palbociclib in patients; however, among patients with de novo metastatic disease, the use of abemaciclib was more effective than ribociclib and palbociclib, and more effective than palbociclib in patients with poorer Eastern Cooperative Oncology Group Performance Status [ECOG PS]. Moreover, among patients who were older or had bone-only disease, the use of the three CDK4/6is were equally effective.Also, in comparison with palbociclib, abemaciclib and ribociclib were associated with better rwPFS, time to next treatment or death (TTNT-D), time to chemotherapy or death (TTC-D), and overall survival (OS).The authors concluded that the three CDK4/6 inhibitors exhibit varying real-world effectiveness, and their large-scale study offers the first real-world evidence to guide clinicians in selecting the most appropriate CDK4/6i for patients diagnosed with HR+/HER2- aBC, considering patient and tumor-specific factors, as well as efficacy, safety, and cost.<h3>Reference</h3>Provenzano L, et al. &nbsp;Annals of Oncology. &nbsp;2025 Apr 7:S0923-7534(25)00134-6. doi: <a href="https://doi.org/10.1016/j.annonc.2025.03.023" target="_blank" rel="noopener">https://doi.org/10.1016/j.annonc.2025.03.023</a>.

Jordana Jampel

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Latest News

PALMARES-2 Study Highlights Variable Efficacy of CDK4/6 Inhibitors in HER2-Negative Advanced Breast Cancer

HR Breast Cancer

Real-world data reveal varying efficacy of CDK4/6 inhibitors in HR+/HER2- aBC, supporting personalized treatment choices.

PALMARES-2 Study: Variable Efficacy of CDK4/6 Inhibitors in HER2-Negative Advanced Breast Cancer

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe